Trial register facet
Trial records in type 2 diabetes mellitus
247 records bearing on type 2 diabetes mellitus.
Showing 0 records on this page
Records
247 documents · page 1 of 11
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| STRIDE | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 792 | 2025 | Moderate |
| SOUL | Semaglutide, oral | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 9,650 | 2025 | Moderate |
| SURPASS-CVOT | Tirzepatide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 13,299 | 2025 | Moderate |
| ATTAIN-2 | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Not rated |
| ACHIEVE-1 | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Not rated |
| ACHIEVE-2 | Orforglipron | Phase 3 | Reported | Randomised, double-blind, active-controlled | — | 2025 | Not rated |
| REDEFINE-2 | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 1,206 | 2025 | Moderate |
| ECNO-PH3-CN-T2D | Ecnoglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Not rated |
| SURPASS-CVOT-PKprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| ATTAIN-2-ELDERLYprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ACHIEVE-1-REGIONAL-JPprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ACHIEVE-2-ELDERLYprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| REDEFINE-2-OLEprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Single-arm open-label | — | 2025 | Very low |
| SOUL-RENAL-IMPprogramme record | Semaglutide, oral | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| STRIDE-QOLprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ECNO-PH3-CN-T2D-ELDERLYprogramme record | Ecnoglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| SURPASS-CVOT-RENAL-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| ATTAIN-2-OLEprogramme record | Orforglipron | Phase 3 | Reported | Single-arm open-label | — | 2025 | Very low |
| ACHIEVE-1-BODY-COMPprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ACHIEVE-2-OLEprogramme record | Orforglipron | Phase 3 | Reported | Single-arm open-label | — | 2025 | Very low |
| REDEFINE-2-ELDERLYprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| SOUL-PKprogramme record | Semaglutide, oral | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| STRIDE-REGIONAL-CNprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ECNO-PH3-CN-T2D-OLEprogramme record | Ecnoglutide | Phase 3 | Reported | Single-arm open-label | — | 2025 | Very low |
page 1 of 11